MedDay Pharmaceuticals multiple sclerosis
MedDay completes patient enrolment in Phase III MD1003 trial
MedDay Pharmaceuticals has completed patient enrolment in the SPI2 Phase III clinical trial evaluating MD1003 for the treatment of progressive…
